Clinical Trials Browser

Acrocephalosyndactylia × Genitourinary × Clear all

NCT05567185 2026-03-13

TAR-210

Phase 1 Active not recruiting

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT07292168 2026-01-21

TAGNOT

Phase 1/2 Recruiting

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02872714 2025-08-14

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Phase 2 Completed

263 enrolled 20 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell

NCT04045613 2023-10-13

FIDES-02

Phase 1/2 Completed

95 enrolled 25 charts

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04972253 2022-08-10

(BLASST)-3

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Phase 2 Completed

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma